TimesSquare Capital Management LLC Acquires Shares of 166,357 Dianthus Therapeutics, Inc. $DNTH

Key Points

• TimesSquare Capital Management initiated a position in Dianthus Therapeutics, purchasing 166,357 shares valued at approximately $16.2 million, or 0.30% of the company. Institutional investors collectively own 47.53% of DNTH.
• Company insiders have sold 284,306 shares worth about $29.3 million over the past 90 days, including substantial sales by CEO Marino Garcia and SVP Adam Veness.
• DNTH shares opened at $114.86, near their 52-week high of $116.89. Analysts maintain a “Moderate Buy” consensus with an average price target of $124.27, despite the company missing quarterly EPS expectations and continuing to report losses.

TimesSquare Capital Management LLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 166,357 shares of the company's stock, valued at approximately $16,216,000. TimesSquare Capital Management LLC owned 0.30% of Dianthus Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics in the second quarter worth about $27,000. First Horizon Corp bought a new stake in Dianthus Therapeutics during the 1st quarter valued at about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at about $40,000. Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC boosted its position in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after buying an additional 3,317 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Insider Activity at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the sale, the senior vice president owned 3,833 shares of the company's stock, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares in the company, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 284,306 shares of company stock valued at $29,289,369 over the last 90 days. Insiders own 3.02% of the company's stock.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $114.86 on Tuesday. The company has a 50 day moving average price of $98.15 and a 200-day moving average price of $83.52. Dianthus Therapeutics, Inc. has a fifty-two week low of $20.31 and a fifty-two week high of $116.89. The stock has a market capitalization of $6.28 billion, a PE ratio of -27.68 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of research reports. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. HC Wainwright increased their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Wedbush raised their price objective on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $124.27.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source